^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GPC3-CAR and IL15 plus IL21

    i
    Associations

    News

    Trials
    Company:
    Baylor College of Medicine
    Drug class:
    GPC-3-targeted CAR-T immunotherapy, IL-15-targeted CAR-T immunotherapy, IL-21-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    7ms
    Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=24, Recruiting, Baylor College of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GPC3 (Glypican 3)
    |
    cyclophosphamide • fludarabine IV • GPC3-CAR and IL15 plus IL21
    1year
    Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Baylor College of Medicine
    New P1 trial • CAR T-Cell Therapy
    |
    GPC3-CAR and IL15 plus IL21
    over3years
    Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Baylor College of Medicine | Trial completion date: Jul 2040 --> Jul 2041 | Initiation date: Jul 2022 --> Jul 2023 | Trial primary completion date: Aug 2025 --> Aug 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    GPC3 (Glypican 3)
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GPC3-CAR and IL15 plus IL21
    4years
    Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Baylor College of Medicine
    Clinical • New P1 trial
    |
    GPC3 (Glypican 3)
    |
    GPC3 positive
    |
    fludarabine IV • GPC3-CAR and IL15 plus IL21 • cyclophosphamide intravenous